Trending...
- California: Governor Newsom announces appointments 1.2.2026
- JS Gallery Brings Global Voices to LA Art Show 2026 with "OFF SCRIPT" Exhibition
- California: Governor Newsom issues proclamation declaring 2026 statewide primary election date
ANNAPOLIS, Md., Jan. 10, 2025 ~ In an exciting announcement, Alphyn, a clinical-stage dermatology company, revealed that their CEO Neal Koller will be presenting at several investor conferences during the upcoming J.P. Morgan Healthcare Week in San Francisco.
The first conference, Biotech Showcase, will take place on January 13th at 10:45 a.m. at the Hilton San Francisco Union Square. Mr. Koller will then move on to the Redefining Every Stage of Investment (RESI) JPM conference on January 14th at 11 a.m. at the San Francisco Marriott Marquis. He has been selected as a finalist in the RESI Innovators Pitch Challenge.
Later that same day, Mr. Koller will also be speaking at NEXUS 2025 from 3 p.m. to 9 p.m. at the Hanger in South San Francisco. During these presentations, he will provide an overview of Alphyn's corporate developments and discuss their lead product candidate, Zabalafin Hydrogel.
More on The Californer
Zabalafin Hydrogel is currently in development to treat atopic dermatitis (AD), a chronic skin condition that affects millions of people worldwide. It is set to begin Phase 2b clinical trials this year and has shown promising results in treating all aspects of AD - including bacterial causes and exacerbation of the disease, as well as managing symptoms such as itchiness, inflammation, and infection.
Alphyn's second candidate is aimed at treating epidermolysis bullosa, a group of rare and potentially fatal skin diseases. With these innovative Multi-Target Therapeutics®, Alphyn hopes to make significant advancements in the field of dermatology and improve the quality of life for those suffering from these conditions.
Investors and industry professionals alike are eagerly anticipating Mr. Koller's presentations and updates on Alphyn's groundbreaking clinical programs during J.P Morgan Healthcare Week next week in San Francisco.
The first conference, Biotech Showcase, will take place on January 13th at 10:45 a.m. at the Hilton San Francisco Union Square. Mr. Koller will then move on to the Redefining Every Stage of Investment (RESI) JPM conference on January 14th at 11 a.m. at the San Francisco Marriott Marquis. He has been selected as a finalist in the RESI Innovators Pitch Challenge.
Later that same day, Mr. Koller will also be speaking at NEXUS 2025 from 3 p.m. to 9 p.m. at the Hanger in South San Francisco. During these presentations, he will provide an overview of Alphyn's corporate developments and discuss their lead product candidate, Zabalafin Hydrogel.
More on The Californer
- Banned Iranian Psychological Thriller THE TURTLE Set for UK Theatrical Release
- Formfy Launches All-in-One E-Signature Platform With Forms, Scheduling & Payments Starting at $19/Mo
- Long Beach Department of Health and Human Services Reaffirms Support for American Academy of Pediatrics Vaccine Schedule
- Navore Market Launches First-Ever Aggregation Hub in La Jolla, Expanding Access to Local Food
- Marc Westray of Interpreters Unlimited named to 2026 Leaders of Influence List
Zabalafin Hydrogel is currently in development to treat atopic dermatitis (AD), a chronic skin condition that affects millions of people worldwide. It is set to begin Phase 2b clinical trials this year and has shown promising results in treating all aspects of AD - including bacterial causes and exacerbation of the disease, as well as managing symptoms such as itchiness, inflammation, and infection.
Alphyn's second candidate is aimed at treating epidermolysis bullosa, a group of rare and potentially fatal skin diseases. With these innovative Multi-Target Therapeutics®, Alphyn hopes to make significant advancements in the field of dermatology and improve the quality of life for those suffering from these conditions.
Investors and industry professionals alike are eagerly anticipating Mr. Koller's presentations and updates on Alphyn's groundbreaking clinical programs during J.P Morgan Healthcare Week next week in San Francisco.
Filed Under: Business
0 Comments
Latest on The Californer
- Revenue Optics Appoints Ljupco Icevski as Executive Advisor in Strategic Move to Accelerate Commercial Development
- Waarom brand mentions in ChatGPT steeds belangrijker worden
- AI Trading Explained: How Bots Beat the Market! with 127%
- Destination: Scientology Shines with Team Spirit in Columbus at 2025 Dotcomm Awards
- Melospeech Expands Pediatric Reach With Addition of Occupational Therapy and Early Childhood Education in San Diego in 2026
- The Best Affordable Luxury Bracelets to Shop in 2026: Timeless Style, Everyday Elegance & Lasting Shine
- Glossa Launches Categories: AI-Powered Quality Analysis That Strengthens Requirements
- Glossa Launches AI-Powered Requirements Platform to Transform Software Implementations
- California: Governor Newsom's statement on Valero's Benicia refinery update
- California: Governor Newsom announces appointments 1.6.2026
- California: Governor Newsom lowers flags, proclaims January 7th as day of remembrance for Los Angeles fires
- Renowned Psychic Medium and Author Samantha McManus Expands Her Impact with New Offerings and Discounts
- Yunishigawa Onsen's Annual "Kamakura Festival" will be held January 30 – March 1, 2026
- California: THIS WEEK: State finance director to hold media briefing on Governor Newsom's 2026-27 budget
- Delta High End Appliance Repair Expands Appliance Repair Services in San Francisco Bay Area
- At Your Service Plumbing Named a 2025 Nextdoor Neighborhood Fave
- California: On eve of LA Fire Anniversary, Governor Newsom announces housing push to keep survivors in their communities
- 113 Digital Media Announces the Visibility +PR Alignment Package
- Snell & Wilmer Attorney Gregory J. Sonnenberg Named Chair of CRF-OC's Associate Board of Directors
- California: As federal aid stalls, Governor Newsom announces proposed effort to close insurance gaps for LA fire survivors, expands mortgage relief